[CAS NO. 1902954-60-2] Abeprazan
PRODUCTS SPECIFICATIONS [1902954-60-2]
DESCRIPTION [1902954-60-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 410.41 |
| Molecular Formula | C19H17F3N2O3S |
| SMILES | CNCC1=CN(S(=O)(C2=CC=CC(F)=C2)=O)C(C3=CC=C(F)C=C3F)=C1OC |
Summary
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H + , K + - ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases [1] .
In Vitro
The mechanism of action of Abeprazan is reversibly binding to H + , K + ‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Abeprazan inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05614752 | Daewoong Pharmaceutical Co. LTD. |
Gastroesophageal Reflux Disease
|
July 6, 2022 | |
| NCT05574374 | Daewoong Pharmaceutical Co. LTD. |
Drug Drug Interaction
|
September 21, 2022 | Phase 1 |
| NCT04888819 | Konkuk University Medical Center|Daewoong Pharmaceutical Co. LTD. |
Erosive Esophagitis
|
February 1, 2021 | Not Applicable |
| NCT04490434 | Daewoong Pharmaceutical Co. LTD. |
Healthy Male Volunteers
|
June 19, 2020 | Phase 1 |
| NCT04341428 | Daewoong Pharmaceutical Co. LTD. |
Healed Erosive Esophagitis
|
July 2, 2020 | Phase 3 |
| NCT04167267 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
November 2019 | Phase 1 |
| NCT04185805 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
December 14, 2019 | Phase 1 |
| NCT04827472 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
January 20, 2021 | Phase 1 |
| NCT05304845 | Daewoong Pharmaceutical Co. LTD. |
Drug Drug Interaction
|
March 21, 2022 | Phase 1 |
| NCT04328766 | Daewoong Pharmaceutical Co. LTD. |
Drug-drug Interaction
|
September 6, 2020 | Phase 1 |
| NCT03184324 | Daewoong Pharmaceutical Co. LTD. |
Erosive Gastroesophageal Reflux Disease
|
August 28, 2017 | Phase 2 |
| NCT04784910 | Daewoong Pharmaceutical Co. LTD. |
Peptic Ulcer
|
March 2021 | Phase 3 |
| NCT02757144 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
March 2016 | Phase 1 |
| NCT05149274 | Daewoong Pharmaceutical Co. LTD. |
Phase 1 Study, Healthy Volunteers
|
October 1, 2021 | Phase 1 |
| NCT04003441 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
June 2019 | Phase 1 |
| NCT04613895 | Daewoong Pharmaceutical Co. LTD.|Hanyang University |
Erosive Esophagitis
|
November 17, 2020 | Not Applicable |
| NCT03574415 | Daewoong Pharmaceutical Co. LTD. |
Healthy Volunteers
|
November 1, 2018 | Phase 1 |
| NCT03811080 | Daewoong Pharmaceutical Co. LTD. |
Non-Erosive Gastroesophageal Reflux Disease
|
February 7, 2019 | Phase 3 |
| NCT03736369 | Daewoong Pharmaceutical Co. LTD. |
Erosive Esophagitis
|
December 13, 2018 | Phase 3 |
| NCT03487562 | Daewoong Pharmaceutical Co. LTD. |
Healthy
|
April 8, 2018 | Phase 1 |
| NCT04341454 | Daewoong Pharmaceutical Co. LTD. |
Acute Gastritis|Chronic Gastritis
|
June 2, 2020 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 121.83 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4366 mL | 12.1829 mL | 24.3659 mL |
| 5 mM | 0.4873 mL | 2.4366 mL | 4.8732 mL |
| 10 mM | 0.2437 mL | 1.2183 mL | 2.4366 mL |